{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:26:50Z","timestamp":1784690810678,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aims to compare the effectiveness and safety of methylprednisolone pulse versus docetaxel in treating recurrent thymoma with myasthenia gravis (MG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center, open-label, retrospective study that included 90 patients with thymoma recurrence accompanied by MG, who were treated with either methylprednisolone pulse or docetaxel. Compared the improvement rate of the Myasthenia Gravis Foundation of America Post-intervention Status (MGFA-PIS) and Quantitative Myasthenia Gravis Score (QMGS), changes in acetylcholine receptor antibodies (AchR-AB), and alterations in thymoma after treatment. Adverse events were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both treatments significantly reduced QMGS and AchR-AB levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). For MG, the overall effective rate (ORR1) was similar between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). However, the methylprednisolone group showed a higher objective response rate (ORR2) and disease control rate (DCR) for thymoma (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The incidence of adverse reaction incidence was 66.7% for the methylprednisolone group and 44.4% for the docetaxel group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Methylprednisolone is more effective against thymoma than docetaxel for recurrent thymoma with MG, but has greater side effects. Docetaxel has similar MG efficacy compared to methylprednisolone, and with fewer side effects. The choice of treatment should be based on the patient\u2019s specific clinical situation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1615529","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:27:11Z","timestamp":1766125631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1006-2963.2021.01.001","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)","volume":"28","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7655\/NYDXBNS.20231015","article-title":"Surgical treatment and prognosis analysis of thymoma alone and thymoma combined with myasthenia gravis","volume":"43","author":"Pan","year":"2023","journal-title":"J Nanjing Med Univ (Nat Sci)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz334","article-title":"Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database","volume":"57","author":"Na","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1053\/j.semtcvs.2016.04.002","article-title":"Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases","volume":"28","author":"Kaufman","year":"2016","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3969\/j.issn.1002-7386.2018.18.020","article-title":"Efficacy study of paclitaxel liposomes and docetaxel in treating thymoma accompanied by myasthenia gravis","volume":"40","author":"Qi","year":"2018","journal-title":"Hebei Med J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e1750","DOI":"10.1002\/cnr2.1750","article-title":"Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: a 20-year single-institution experience","volume":"6","author":"Altshuler","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/ejcts\/ezt649","article-title":"Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database","volume":"46","author":"Ruffini","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1172\/JCI111757","article-title":"Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation","volume":"75","author":"Cupps","year":"1985","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1212\/wnl.30.5.557","article-title":"Humoral immunity in myasthenia gravis: effect of steroids and thymectomy","volume":"30","author":"Tindall","year":"1980","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00281-020-00827-8","article-title":"Control of immunity by glucocorticoids in health and disease","volume":"42","author":"Shimba","year":"2020","journal-title":"Semin Immunopathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.049","article-title":"Imbalance of circulating CD4(+)CXCR5(+)FOXP3(+) Tfr-like cells and CD4(+)CXCR5(+)FOXP3(\u2212) Tfh-like cells in myasthenia gravis","volume":"630","author":"Wen","year":"2016","journal-title":"Neurosci Lett"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.imbio.2012.05.006","article-title":"SDF-1\/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients","volume":"218","author":"Weiss","year":"2013","journal-title":"Immunobiology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1210\/jcem-12-6-690","article-title":"Effect of ACTH on thymic masses","volume":"12","author":"Soffer","year":"1952","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","first-page":"476","article-title":"Regression of malignant thymoma with metastases after treatment with adrenocortical steroids","volume":"14","author":"Almog","year":"1978","journal-title":"Isr J Med Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0936-6555(05)80783-6","article-title":"Dramatic response of recurrent invasive thymoma to high doses of corticosteroids","volume":"4","author":"Kirkove","year":"1992","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0300-2977(01)00090-0","article-title":"Regression of invasive thymoma following corticosteroid therapy","volume":"58","author":"Termeer","year":"2001","journal-title":"Neth J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/cncr.21875","article-title":"Preoperative steroid pulse therapy for invasive thymoma: clinical experience and mechanism of action","volume":"106","author":"Kobayashi","year":"2006","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ejcts.2007.02.032","article-title":"Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms","volume":"31","author":"Barratt","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"584703","DOI":"10.3389\/fimmu.2021.584703","article-title":"Remission of Thymoma on steroid therapy in a patient with atypical Thymoma-associated multiorgan autoimmunity: a case report and literature review","volume":"12","author":"Wrona","year":"2021","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.resinv.2024.06.008","article-title":"The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas","volume":"62","author":"Tanaka","year":"2024","journal-title":"Respir Investig"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1002\/cncr.26061","article-title":"Steroid receptor expression in thymomas and thymic carcinomas","volume":"117","author":"Mimae","year":"2011","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00432-004-0646-8","article-title":"Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells","volume":"131","author":"Funakoshi","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41435-025-00329-3","article-title":"Novel modulation of T effector memory cells-expressing CD45RA by prednisone in inoperable advanced type B thymoma patients","volume":"26","author":"Yu","year":"2025","journal-title":"Genes Immun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s004280000333","article-title":"Histopathologic changes of thymoma preoperatively treated with corticosteroids","volume":"438","author":"Tateyama","year":"2001","journal-title":"Virchows Arch"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00210-023-02641-z","article-title":"Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway","volume":"397","author":"Liu","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s12672-025-02700-2","article-title":"Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone","volume":"16","author":"Gu","year":"2025","journal-title":"Discov Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","article-title":"The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis","volume":"33","author":"Safipour","year":"2022","journal-title":"Osteoporos Int"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40120-023-00442-3","article-title":"Identification of potential serum protein biomarkers in Thymoma with myasthenia gravis after docetaxel treatment","volume":"12","author":"Yang","year":"2023","journal-title":"Neurol Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/1940-6207.CAPR-20-0161","article-title":"Long-term glucocorticoid use and Cancer risk: a population-based cohort study in South Korea","volume":"13","author":"Oh","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1615529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:27:14Z","timestamp":1766125634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1615529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":41,"alternative-id":["10.3389\/fneur.2025.1615529"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1615529","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1615529"}}